The annual JP Morgan medical healthcare conference was held in San Francisco, on Jan 15.

Michael Yu, chairman of Innovent Biologics and Yang Dajun, chairman of Ascentage Pharma, two representative entrepreneurs from Suzhou bio-pharmaceutical industry, gave road show speeches at the conference.

JP Morgan medical healthcare conference held at the beginning of every year is a gathering for investors in medical healthcare industry with the longest history and largest scale. It is regarded by insiders as the wind vane of the bio-pharmaceutical industry of the year.

The conference this year, with the theme of sharing the development tendency of biotech companies and pharmaceutical enterprises, has attracted 15,000 senior executives, entrepreneurs and investors all over the world.

In their speech, Yu and Yang shared the latest financing of their companies and the R&D plan in 2017 with the participants.

Besides Innovent Biologics and Ascentage Pharma, CStone Pharmaceuticals from Suzhou Biobay also attended the conference. It successfully raised $150 million in series A funding, a record high in China’s series A funding in bio-pharmaceutical sector. Of the 2016 Top 10 of Global Bio-technology Company funding by PWC, CStone Pharmaceuticals ranked the sixth.

Jin Kewen, chairman of BayHelix Group, an organization composed of outstanding Chinese entrepreneurs in life science and medical healthcare industry, said, “We are looking forward to the innovative transformation mode and solutions from the new thoughts brought by Chinese leading figures in bio-pharmaceutical industry so as to bring more good news to the patients.”

Suzhou Biobay has attracted over 460 various bio-pharmaceutical enterprises for entrepreneurship and innovation and formed the industry clusters featured by new medicine development, medical apparatus and bio-technology. Currently the innovative medical flagship projects like BeiGene, ZAI Lab, Lexenpharm have already settled in Suzhou Biobay.